Cross-border transactions for innovative drugs developed in China have surged to a record US$110 billion in the first half of 2026, according to Chinese state media reports published Monday. The figure marks the highest six-month total ever recorded for such deals, state media said. By June 30, 81 separate agreements had been concluded, a volume that already equals roughly 80 percent of the total deal count for all of 2025.
State media reports described the first-half performance as a record, though officials did not clarify whether the US$110 billion figure represents total deal value, cumulative licensing fees, or another financial metric. The buyers in these transactions came from 20 countries and regions, with the United States, the United Kingdom, France, and Italy cited as the primary sources.
The deals spanned 10 therapeutic areas, including oncology, metabolic diseases, immunology, and neurology. The surge reflects China’s rapidly expanding role in global pharmaceutical development, state media concluded. The pace of dealmaking in the first six months of 2026 accelerated sharply compared with the previous year, continuing a steady increase in cross-border transactions that state and international reports have tracked over recent years.
China’s Pharmaceutical Sector Rises Amid Broader Economic Shift
The milestone in drug dealmaking does not occur in isolation. China’s pharmaceutical industry has been expanding its research capabilities and actively seeking international partnerships for drug candidates developed domestically.
This growth mirrors the broader transformation of China’s economy. After millennia of imperial rule that followed the Qin and Han dynasties, the 1911 Revolution ended the empire and led to the Republic of China. Following a civil war and the Second Sino-Japanese War, the People’s Republic of China was proclaimed in 1949.
Economic reform and opening-up policies beginning in 1978 moved the nation toward a socialist market economy. Today, China is a global superpower, the world’s largest manufacturer, and the second-largest economy.
Its influence extends into science, technology, and geopolitics, and it holds a permanent seat on the United Nations Security Council. The growth of the pharmaceutical sector is a direct reflection of this broader economic expansion. Increased international dealmaking allows domestic firms to realign their competitive positions and helps the country expand its role in global health and innovation.
By licensing drug candidates to partners in the United States, Europe, and beyond, Chinese companies are securing capital, expertise, and market access that were less available a decade ago.
Acceleration and Open Questions for Second Half of 2026
The first-half 2026 data represents an acceleration of a trend already underway. State media noted that the 81 deals sealed by June 30 already approach the full-year deal volume for 2025, indicating that the pace of activity has intensified markedly.
Observers will be watching to see whether this momentum carries into the second half of the year. Key questions include whether the therapeutic areas that dominated the first half — particularly oncology and metabolic diseases — will remain the primary focus for international buyers, and whether the number of deals continues to climb at a similar rate. The US$110 billion figure, while celebrated by Chinese state media, leaves analysts without a precise measure of its meaning.
Officials have not specified whether the number aggregates the total announced value of each transaction, the sum of upfront and milestone payments, or another definition. Despite the ambiguity, the scale and speed of the deals underscore how deeply China has integrated into the global pharmaceutical supply chain.
As Chinese companies produce more innovative drug candidates and seek partnerships overseas, the country’s pharmaceutical footprint is likely to keep expanding, reshaping international competition and collaboration in drug development.
